Latest Columbia Laboratories (CBRX) Headlines
Columbia Laboratories Shares Up 27.8% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - 1 hr 2 mins ago
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 27.82% as of today's recent price of $7.19.
Columbia Laboratories announces buy back of 1.4m common shares
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) revealed on Friday the repurchase of 1.4m shares of its common stock.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Columbia Laboratories posts lesser net income of USD6.7m in 2013
M2 - Thu Mar 06, 4:41AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) disclosed on Wednesday its net income of USD6.7m (USD0.59 per basic & USD0.52 per diluted share) for the 12 month periods ended 31 December 2013.
Columbia Laboratories Up 20.4% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Wed Mar 05, 11:12AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 20.36% as of today's recent price of $6.77.
Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 05, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013.
Columbia Laboratories adds Donald H. Hunter to board
M2 - Tue Mar 04, 5:20AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Monday that Donald H. Hunter has been elected to its board of directors as well as to its audit committee.
Columbia Laboratories Announces Board Changes
PR Newswire - Mon Mar 03, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee.
Uptrend Call Working As Columbia Laboratories Stock Rises 22.5% (CBRX)
Comtex SmarTrend(R) - Wed Feb 26, 9:50AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 22.49% as of today's recent price of $6.89.
Columbia Laboratories to Discuss Fourth Quarter and Year End 2013 Financial Results on March 5 Conference Call
PR Newswire - Wed Feb 26, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:
Biotech Stocks Triggering Breakout Trades: Columbia Labs
at The Street - Thu Feb 20, 7:25AM CST
Here's how to trade this under-$10 biotech stock.
3 Biotech Stocks on the Verge of Breakouts: Amarin, Star Scientific, Columbia Labs
at The Street - Thu Feb 20, 5:00AM CST
These three biotech stocks trading for under $10 are within range of triggering breakout trades.
Columbia Laboratories, Inc. Announces Restatement of Previously- Issued Unaudited Interim Consolidated Financial Statements for the Three- and Nine-Month Periods Ended September 30, 2013
PR Newswire - Wed Feb 19, 5:07PM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced a restatement of its previously-issued unaudited interim consolidated financial statements for the three- and nine-month periods ended September 30, 2013 due to a calculation error related to its common stock warrant expense, a non-cash item, for these periods.
Shares of CBRX Up 21.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 19, 9:19AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 21.24% as of today's recent price of $6.82.
Columbia Laboratories Shares Up 19.1% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Feb 11, 5:07PM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 19.11% as of today's recent price of $6.70.
Columbia Laboratories Has Returned 18.9% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Feb 04, 11:14AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 18.93% as of today's recent price of $6.69.
Columbia Laboratories to Present February 11th at BIO CEO & Investor Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Frank Condella, President and Chief Executive Officer of Columbia Laboratories Inc. (Nasdaq: CBRX) will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference. The presentation is scheduled as follows:
Columbia Laboratories Has Returned 25.5% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Jan 21, 9:26AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 25.51% as of today's recent price of $7.06.
Columbia Laboratories Shares Up 27.8% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - 1 hr 2 mins ago
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 27.82% as of today's recent price of $7.19.
Columbia Laboratories announces buy back of 1.4m common shares
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) revealed on Friday the repurchase of 1.4m shares of its common stock.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Columbia Laboratories posts lesser net income of USD6.7m in 2013
M2 - Thu Mar 06, 4:41AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) disclosed on Wednesday its net income of USD6.7m (USD0.59 per basic & USD0.52 per diluted share) for the 12 month periods ended 31 December 2013.
Columbia Laboratories Up 20.4% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Wed Mar 05, 11:12AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 20.36% as of today's recent price of $6.77.
Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 05, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013.
Columbia Laboratories adds Donald H. Hunter to board
M2 - Tue Mar 04, 5:20AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Monday that Donald H. Hunter has been elected to its board of directors as well as to its audit committee.
Columbia Laboratories Announces Board Changes
PR Newswire - Mon Mar 03, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee.
Uptrend Call Working As Columbia Laboratories Stock Rises 22.5% (CBRX)
Comtex SmarTrend(R) - Wed Feb 26, 9:50AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 22.49% as of today's recent price of $6.89.
Columbia Laboratories to Discuss Fourth Quarter and Year End 2013 Financial Results on March 5 Conference Call
PR Newswire - Wed Feb 26, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:
Biotech Stocks Triggering Breakout Trades: Columbia Labs
at The Street - Thu Feb 20, 7:25AM CST
Here's how to trade this under-$10 biotech stock.
3 Biotech Stocks on the Verge of Breakouts: Amarin, Star Scientific, Columbia Labs
at The Street - Thu Feb 20, 5:00AM CST
These three biotech stocks trading for under $10 are within range of triggering breakout trades.
Columbia Laboratories, Inc. Announces Restatement of Previously- Issued Unaudited Interim Consolidated Financial Statements for the Three- and Nine-Month Periods Ended September 30, 2013
PR Newswire - Wed Feb 19, 5:07PM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced a restatement of its previously-issued unaudited interim consolidated financial statements for the three- and nine-month periods ended September 30, 2013 due to a calculation error related to its common stock warrant expense, a non-cash item, for these periods.
Shares of CBRX Up 21.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 19, 9:19AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 21.24% as of today's recent price of $6.82.
Columbia Laboratories Shares Up 19.1% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Feb 11, 5:07PM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 19.11% as of today's recent price of $6.70.
Columbia Laboratories Has Returned 18.9% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Feb 04, 11:14AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 18.93% as of today's recent price of $6.69.
Columbia Laboratories to Present February 11th at BIO CEO & Investor Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Frank Condella, President and Chief Executive Officer of Columbia Laboratories Inc. (Nasdaq: CBRX) will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference. The presentation is scheduled as follows:
Columbia Laboratories Has Returned 25.5% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Jan 21, 9:26AM CST
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 6 months, Columbia Laboratories has returned 25.51% as of today's recent price of $7.06.
